Biophytis SA (FR:ALBPS) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Biophytis SA has received FDA approval to commence a phase 2 clinical study of BIO101 for obesity, focusing on muscle strength and mobility improvements. Anticipated to start in mid-2024 in the USA, the study’s prelim results are expected in 2025. The company is actively seeking funding and partnerships to advance this study in the growing obesity treatment market.
For further insights into FR:ALBPS stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money